Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL1 CAR-T Followed by Allo-HSCT in R/R AML
NCT07342244Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CB-012 in acute myeloid leukemia (AML). Primary endpoint: Overall Survival at 24 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
CB-012
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07342244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342244.